ChinaDaily Briefs

Daily Brief China: Ant Financial Services Group, Alibaba Group, Youlife International Holdings, Yanlord Land, Perfect Group Corp Ltd, Shanghai Junshi Bioscience Co. Ltd. and more

In today’s briefing:

  • Ant Group: Shareholder Restructuring Announced and the Lack of IPO Plan Are Negatives Surprise
  • China Internet Weekly (9Jan2023): Ant Group, Alibaba, Tencent, ByteDance, China Literature
  • Youlife International Pre-IPO Tearsheet
  • Morning Views Asia: Sands China, SJM Holdings, Yanlord Land
  • Perfectly Imperfect
  • Ant Group Completed Equity Structure Adjustment
  • Shanghai Junshi Bioscience (1877.HK/688180.CH)- Junshi Has Changed Its Story from Tumor to COVID-19?

Ant Group: Shareholder Restructuring Announced and the Lack of IPO Plan Are Negatives Surprise

By Victor Galliano

  • The announced restructuring of Ant Group holding companies will block founder Jack Ma from achieving majority voting on the board following the implementation of the holdcos adjustment
  • The majority of board directors will be “independent” post the holdco restructuring and they are likely to drive a more social policy focused agenda, as the 2021 sustainability report suggests
  • We see these developments, and especially the lack of IPO plan, to be negative for non-government aligned Ant Group shareholders, such as the international private equity groups and especially Alibaba

China Internet Weekly (9Jan2023): Ant Group, Alibaba, Tencent, ByteDance, China Literature

By Ming Lu

  • A state-owned company invested in Ant Group, which boosted Alibaba’s stock price.
  • Tencent obtained five new game licenses in December, three of which are imported games.
  • China Literature’s daily active users increased by 80% in 2022 and reached the historical high.

Youlife International Pre-IPO Tearsheet

By Ethan Aw

  • Youlife International Holdings (1759732D CH) is looking to raise at least US$100m in its upcoming HK IPO. The deal will be run by Macquarie and CCB International. 
  • Youlife International is a blue-collar lifetime service platform in China. It assists blue-collar talent with upskilling and lifetime career development. 
  • According to CIC, Youlife ranked first among all blue-collar lifetime service platforms in China in terms of revenue generated from blue-collar lifetime services in 2021. 

Morning Views Asia: Sands China, SJM Holdings, Yanlord Land

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Perfectly Imperfect

By subSPAC

  • Artificial Intelligence (AI) and Deep Learning Applications are all the rage, primarily thanks to the likes of OpenAI’s ChatGPT being used for text and Dall-E being used to generate digital images.
  • ChatGPT’s popularity has soared, reaching a user base of 1 million users in 5 days, and OpenAI itself is benefiting from the surge in users, now valued at $29 Billion.
  • Investors are already looking for the next wave of AI products that can make a big splash and potentially disrupt legacy industries. 

Ant Group Completed Equity Structure Adjustment

By Xin Yu, CFA

  • CBIRC approved the capital replenishment plan of RMB10.5bn of Ant CFC on Dec 30, 2022
  • Under the regulatory guidance, Ant Group needs to complete a multifaceted rectification plan
  • After the fund raising, Ant Group’s next step is to obtain FHC license and credit bureau license

Shanghai Junshi Bioscience (1877.HK/688180.CH)- Junshi Has Changed Its Story from Tumor to COVID-19?

By Xinyao (Criss) Wang

  • Junshi once generated sales and profits in scale, but lost money again. Its story suddenly changed from cancer drugs to COVID-19. We have lost sight of its development direction.
  • Junshi’s commercialization history has lost its reference value for confirming the outlook. The calculation of peak sales doesn’t make much sense, because they cannot help Junshi turn losses into profits.
  • The current market value still has too much “bubble”, and COVID-19 drug is a major “interference” to the valuation. We analyzed our thoughts on future valuation by excluding COVID-19 projects.  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars